Biogen Buys Apellis Pharmaceuticals for $5.6B to Boost Near-Term Growth
Summary:
Biogen is acquiring Apellis Pharmaceuticals for $5.6 billion to gain two approved drugs – Syfovre and Empaveli – that can drive near-term revenue growth ahead of its late-stage pipeline launches. The deal strengthens Biogen’s position in immunology and kidney diseases while adding commercially active products expected to grow steadily over the next few years.
Combo Therapy Targets “Paradox” BAP1 Mutation Across Multiple Cancers
Summary:
Researchers found that inhibiting LSD1 and PARP1 in BAP1-deficient tumors disrupts DNA repair, leading to tumor shrinkage and improved survival in mouse models across several cancer types. The combination – featuring drugs like Lynparza – could pave the way for broadly effective cancer treatments, though further clinical studies are needed to confirm its potential in humans.
Eli Lilly Bets $6.3B on Sleep Drug Race with Centessa Pharmaceuticals Deal
Summary:
Eli Lilly is acquiring Centessa Pharmaceuticals for $6.3 billion to strengthen its neuroscience pipeline, gaining two clinical-stage drugs targeting OX2R for sleep disorders like narcolepsy. The move fills a key gap in Lilly’s portfolio and positions it to compete with rivals like Takeda Pharmaceutical and Eisai in a potentially multi-billion-dollar market driven by next-generation wakefulness therapies.
U.S. Food and Drug Administration Clears Rocket’s Gene Therapy for Rare Immune Disorder
Summary:
The FDA granted accelerated approval to Kresladi, a gene therapy from Rocket Pharmaceuticals for treating severe Leukocyte Adhesion Deficiency Type 1, offering a potential life-saving option for children who cannot undergo bone marrow transplants. While not expected to be a major commercial product, the approval marks a critical turnaround for Rocket after years of setbacks, providing both clinical validation and financial runway through a valuable priority review voucher.
FDA Tightens Rules on Compounded GLP-1 Drugs as Supply Stabilizes
Summary:
The U.S. Food and Drug Administration clarified that compounded versions of GLP-1 drugs are only allowed while those medicines remain on its shortage list, signaling stricter limits as supply improves. Once shortages end, pharmacies must stop producing copycat versions or risk enforcement, reinforcing that compounding is a temporary exception rather than a long-term alternative to approved treatments.
